Is Sarepta’s Gene Therapy Elevidys Casting Doubt On A Popular DMD Endpoint?

 
• By Derrick Gingery
measuring tape
Will sponsors have to adjust the NSAA after Sarepta said the scale was not sensitive enough to detect patient changes? • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies